Investors in VentiRx Pharmaceuticals Inc. say they expect to get full market value in the take-out price set in last week's option deal with Celgene Corp. (NASDAQ:CELG).

Celgene paid $35 million up front for an option to acquire VentiRx at an undisclosed predetermined price following Phase II trials of VTX-2337 in ovarian and head and neck cancer. The biotech also is eligible for undisclosed payments prior to the option exercise, including an equity investment.